The next major catalyst is PIVOT-006 topline data in November 2026, which could significantly impact the stock if positive or negative. Also watch for BLA submission completion in Q4 2026 and 12-month data from two cohorts in December 2026.
Drug in focus
CGON drug pipeline →cretostimogene
▲ Bullish Named in this press release- Impact
- Phase
- Phase 3
- Time to market
- BLA submission planned for Q4 2026 in BCG-unresponsive NMIBC. If accepted and approved under standard FDA review, potential approval could come in H2 2027. The drug already has Breakthrough Therapy designation from the FDA.
- Next catalyst
- None dated
What to watchWatch for BLA submission completion in Q4 2026, this is the key catalyst that will determine whether cretostimogene becomes the first FDA-approved oncolytic virus therapy for NMIBC. Also monitor PIVOT-006 Phase 3 topline data (intermediate-risk NMIBC), which could be imminent. The $1.05B ATM facility creates ongoing dilution overhang, so positive regulatory catalysts are needed to offset that pressure.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 6 $75.99entry
- T+1 · 8d ago −1.65%α −4.01% · $74.74
- T+5 · 4d ago −2.09%α −4.69% · $74.40
- T+6 · todayOpen
- T+20 · in 20d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
CG Oncology reported Q3 2026 financial results showing a net loss of $56.9 million ($0.64 per share), widening from a $43.8 million loss a year ago, as R&D spending rose 41% to $39.2 million. The company highlighted upcoming key catalysts: PIVOT-006 Phase 3 topline data in November 2026, 12-month data from two cohorts in December 2026, and completion of a BLA submission for BCG-unresponsive NMIBC in Q4 2026. Cash of $984.5 million is sufficient through 2029.
Key Financial Metrics
Key Facts
- Q3 2026 net loss of $56.9 million vs $43.8 million in Q3 2025
- R&D expenses rose to $39.2 million from $27.9 million year-over-year
- Cash, cash equivalents and marketable securities of $984.5 million as of September 30, 2026
- PIVOT-006 Phase 3 topline data expected November 2026
- BOND-003 Cohort P and CORE-008 Cohort CX 12-month data expected December 2026
- BLA submission for BCG-unresponsive NMIBC expected to be completed Q4 2026
- Appointed Isabel Kalofonos as Chief Commercial Officer in October 2026
Financial Impact
Net loss widened by $13.1 million year-over-year; cash burn of $57 million in Q3; cash runway through 2029
Risk Factors
- PIVOT-006 topline data may not meet expectations or may differ from final results
- BLA submission may face delays or FDA may not approve cretostimogene
- Cash burn rate is increasing; actual runway may be shorter than estimated
- Clinical trial results from one cohort may not be predictive of others
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3397495 |
Track record
25 reports on CGON
6 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +26.33% at T+20 after the Jun 12, 2026 report. 8 of 8 went positive at some point.
Filters
- Nov 16, 2026today 8-K Bullish 7/10 Entry $98.84 Now $84.78 −14.23% settles Dec 15
- Nov 16, 2026today Press Release Bullish 7/10 Entry $95.01 Now $84.78 −10.77% settles Dec 15
- Nov 6, 202610d ago 8-K Bearish 5/10 Entry $75.99 Now $84.78 −11.57% settles Dec 7
- Nov 6, 202610d ago Press Release Neutral 4/10 Viewing Entry $75.99 Now $84.78 +11.57% settles Dec 7
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $64.06 Now $84.78 +32.34% settles Dec 2
- Oct 19, 202628d ago 3 Neutral 2/10 Entry $61.93 Now $84.78 +36.90% settles Nov 17
- Oct 15, 20264w ago 144 Neutral 2/10 Entry $59.85 to $74.40 Now $84.78 +41.65% ▲ +24.31% +25.47% vs SPY
- Oct 12, 20265w ago Institutional Cluster Mixed 3/10 Entry $63.13 to $74.74 Now $84.78 +34.29% ▲ +18.39% +21.66% vs SPY
- Aug 6, 202614w ago Press Release Bearish 7/10 Entry $74.85 to $74.33 Now $84.78 −13.27% ▲ +0.69% +1.29% vs SPY
- Aug 6, 202614w ago 424B5 Bearish 6/10 Entry $74.85 to $74.33 Now $84.78 −13.27% ▲ +0.69% +1.29% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers